Stable Response to IL-13 and IL-13/4 Inhibitor Treatment in Moderate-to- Severe AD.
0 SAR
الدفع
المقدمة
هذا الفصل لـ
- Clinical Pharmacy
- Pharmacy
- Physician
- Resident / Fellow
الفئات ذات الصلة
- How Can Response Patterns to Olumiant Inform Clinical Decision-Making in Severe Alopecia Areata?
- Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A Novel Treatment Option for Patients ≥12 Years
- Atopic Dermatitis in Elderly Patients: Discussing the Safety of Lebrikizumab in an 86-Year-Old Patient.
- Key IL-13 Skin and Itch Data in Moderate-to-Severe AD.
- Atopic Dermatitis in Visible Areas Is a Real Challenge!
- Depth of Response & Stability of Response of Lebrikizumab
- Can You Reach EASI Targets Faster? – AD Case with Prof. Naiem Issa
- Deep Response to IL‑13 and IL‑4/13 Inhibition in AD